1046478-89-0

Basic information

• Product Name: tert-butyl 4-(2-tosylhydrazono)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(2-tosylhydrazono)piperidine-1-carboxylate;N’-(1-Boc-piperidin-4-ylidene)-4-methylbenzenesulfonohydrazide
• CAS NO: 1046478-89-0
• Molecular Formula: C₁₇H₂₅N₃O₄S
• Molecular Weight: 367.4631
• Mol File: 1046478-89-0.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 503.4±60.0 °C(Predicted)
• Appearance: /
• Density: 1.24±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 9.54±0.20(Predicted)
• CAS DataBase Reference: tert-butyl 4-(2-tosylhydrazono)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(2-tosylhydrazono)piperidine-1-carboxylate(1046478-89-0)
• EPA Substance Registry System: tert-butyl 4-(2-tosylhydrazono)piperidine-1-carboxylate(1046478-89-0)

Safety Data

• Hazardous Substances Data: 1046478-89-0(Hazardous Substances Data)

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 1576-35-8 toluene-4-sulfonic acid hydrazide 

Downstream Products

• 303975-71-5 tert-butyl 4-(4-methoxyphenyl)piperidine-1-carboxylate 
• 1510865-58-3 tert-butyl 4-(3-nitrophenyl)piperidine-1-carboxylate 
• 85838-94-4 N-Boc-1,2,3,6-tetrahydropyridine 
• 1609483-42-2 4-(4-methoxycarbonylbenzoyl)piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS

The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds, methods of using the compounds and methods of determining the monoacylglycerol lipase (MAGL) inhibitory activity of the compounds.

4-HETEROARYLCARBONYL-N-(PHENYL OR HETEROARYL) PIPERIDINE-1-CARBOXAMIDES AS INHIBITORS OF TANKYRASES

Compounds of the formula (I) in which R1, R2 and R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

FUSED GLYCOSIDASE INHIBITORS

Compounds of formula (I), wherein A, Z, E, R1, R2, m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.